We anticipate that as we learn more about MEK inhibitor usage in ovarian cancer, somatic testing for this gene, especially in patients with MUTYH germline mutations, may aid treatment decisions as it does in colorectal cancer [90]. This evidence concerns the gene MAP2K7 and ovarian carcinoma.